Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ | Breast Cancer | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Ernster  VL, Ballard-Barbash  R, Barlow  WE,  et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography.  J Natl Cancer Inst. 2002;94(20):1546-1554.PubMedGoogle ScholarCrossref
2.
Brinton  LA, Sherman  ME, Carreon  JD, Anderson  WF.  Recent trends in breast cancer among younger women in the United States.  J Natl Cancer Inst. 2008;100(22):1643-1648.PubMedGoogle ScholarCrossref
3.
Ernster  VL, Barclay  J, Kerlikowske  K, Wilkie  H, Ballard-Barbash  R.  Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program.  Arch Intern Med. 2000;160(7):953-958.PubMedGoogle ScholarCrossref
4.
Romero  L, Klein  L, Ye  W,  et al.  Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast.  Am J Surg. 2004;188(4):371-376.PubMedGoogle ScholarCrossref
5.
Donker  M, Litière  S, Werutsky  G,  et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.  J Clin Oncol. 2013;31(32):4054-4059.PubMedGoogle ScholarCrossref
6.
Wärnberg  F, Bergh  J, Zack  M, Holmberg  L.  Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden.  Cancer Epidemiol Biomarkers Prev. 2001;10(5):495-499.PubMedGoogle Scholar
7.
Wärnberg  F, Garmo  H, Emdin  S,  et al.  Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial.  J Clin Oncol. 2014;32(32):3613-3618.PubMedGoogle ScholarCrossref
8.
US Census Bureau. 2007-2011 American Community Survey. Table B19013: Median household income in the past 12 months (in 2011 inflation-adjusted dollars). American Community Survey 5-year estimates. http://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml. Accessed August 10, 2015.
9.
Iqbal  J, Ginsburg  O, Rochon  PA, Sun  P, Narod  SA.  Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.  JAMA. 2015;313(2):165-173.PubMedGoogle ScholarCrossref
10.
Correa  C, McGale  P, Taylor  C,  et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.  J Natl Cancer Inst Monogr. 2010;2010(41):162-177.PubMedGoogle ScholarCrossref
11.
Ernster  VL, Barclay  J, Kerlikowske  K, Grady  D, Henderson  C.  Incidence of and treatment for ductal carcinoma in situ of the breast.  JAMA. 1996;275(12):913-918.PubMedGoogle ScholarCrossref
12.
Lakhani  SR, Ellis  IO, Schnitt  SJ, Tan  PH, van de Vijver  MJ, eds.  WHO Classification of Tumours of the Breast. 4th ed. Lyon: IARC; 2012.
13.
Habel  LA, Daling  JR, Newcomb  PA,  et al.  Risk of recurrence after ductal carcinoma in situ of the breast.  Cancer Epidemiol Biomarkers Prev. 1998;7(8):689-696.PubMedGoogle Scholar
14.
Sanders  ME, Schuyler  PA, Simpson  JF, Page  DL, Dupont  WD.  Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up.  Mod Pathol. 2015;28(5):662-669.PubMedGoogle ScholarCrossref
15.
Wapnir  IL, Dignam  JJ, Fisher  B,  et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.  J Natl Cancer Inst. 2011;103(6):478-488.PubMedGoogle ScholarCrossref
16.
Roses  RE, Arun  BK, Lari  SA,  et al.  Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death.  Ann Surg Oncol. 2011;18(10):2873-2878.PubMedGoogle ScholarCrossref
17.
Collins  LC, Achacoso  N, Haque  R,  et al.  Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.  Breast Cancer Res Treat. 2013;139(2):453-460.PubMedGoogle ScholarCrossref
18.
Bijker  N, Peterse  JL, Duchateau  L,  et al.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.  J Clin Oncol. 2001;19(8):2263-2271.PubMedGoogle Scholar
19.
Fisher  ER, Costantino  J, Fisher  B,  et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: five-year observations concerning lobular carcinoma in situ.  Cancer. 1996;78(7):1403-1416.PubMedGoogle ScholarCrossref
20.
Rakovitch  E, Mihai  A, Pignol  JP,  et al.  Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?  Breast Cancer Res Treat. 2004;87(3):265-272.PubMedGoogle ScholarCrossref
21.
Silverstein  MJ, Lagios  MD, Groshen  S,  et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast.  N Engl J Med. 1999;340(19):1455-1461.PubMedGoogle ScholarCrossref
22.
Rosenberg  J, Chia  YL, Plevritis  S.  The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the US SEER database.  Breast Cancer Res Treat. 2005;89(1):47-54.PubMedGoogle ScholarCrossref
23.
Schairer  C, Mink  PJ, Carroll  L, Devesa  SS.  Probabilities of death from breast cancer and other causes among female breast cancer patients.  J Natl Cancer Inst. 2004;96(17):1311-1321.PubMedGoogle ScholarCrossref
24.
Narod  SA.  Breast cancer in young women.  Nat Rev Clin Oncol. 2012;9(8):460-470.PubMedGoogle ScholarCrossref
25.
Copson  E, Eccles  B, Maishman  T,  et al; POSH Study Steering Group.  Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.  J Natl Cancer Inst. 2013;105(13):978-988.PubMedGoogle ScholarCrossref
26.
McGale  P, Taylor  C, Correa  C,  et al; EBCTCG (Early Breast Cancer Trialists’ Collaborative Group).  Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.  Lancet. 2014;383(9935):2127-2135.PubMedGoogle ScholarCrossref
27.
Fisher  B, Anderson  S, Bryant  J,  et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.  N Engl J Med. 2002;347(16):1233-1241.PubMedGoogle ScholarCrossref
28.
Vargas  C, Kestin  L, Go  N,  et al.  Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.  Int J Radiat Oncol Biol Phys. 2005;63(5):1514-1521.PubMedGoogle ScholarCrossref
29.
Punglia  RS, Schnitt  SJ, Weeks  JC.  Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?  J Natl Cancer Inst. 2013;105(20):1527-1533.PubMedGoogle ScholarCrossref
30.
Omer  ZB, Hwang  ES, Esserman  LJ, Howe  R, Ozanne  EM.  Impact of ductal carcinoma in situ terminology on patient treatment preferences.  JAMA Intern Med. 2013;173(19):1830-1831.PubMedGoogle ScholarCrossref
31.
McCormick  B, Winter  K, Hudis  C,  et al.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.  J Clin Oncol. 2015;33(7):709-715.PubMedGoogle ScholarCrossref
32.
Solin  LJ, Gray  R, Baehner  FL,  et al.  A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.  J Natl Cancer Inst. 2013;105(10):701-710.PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Evidence for Informed Consent
    Robert Weiss M.S. | Independent Lymphedema Patient Advocate
    Among the common long-term effects of over-treatment of DCIS is breast lymphedema, truncal lymphedema and delayed breast cellulitis. In discussions with the patient prior to DCIS or early stage invasive breast cancer the physician must give the patient enough information with which to make a decision on radiotherapy which weighs the risk of (salvageable) local recurrence against the risk of lifelong lymphedema.<br/><br/>I raised this issue in 2008 in a poster at the NLN Conference and am gratified that the evidence is finally being collected to support this unpopular position.<br/><br/>See http://www.lymphactivist.org/breast_lymphedema-1.pdf
    CONFLICT OF INTEREST: None Reported
    Original Investigation
    October 2015

    Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ

    Author Affiliations
    • 1Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario, Canada
    • 2Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
    JAMA Oncol. 2015;1(7):888-896. doi:10.1001/jamaoncol.2015.2510
    Abstract

    Importance  Women with ductal carcinoma in situ (DCIS), or stage 0 breast cancer, often experience a second primary breast cancer (DCIS or invasive), and some ultimately die of breast cancer.

    Objective  To estimate the 10- and 20-year mortality from breast cancer following a diagnosis of DCIS and to establish whether the mortality rate is influenced by age at diagnosis, ethnicity, and initial treatment received.

    Design, Setting, and Participants  Observational study of women who received a diagnosis of DCIS from 1988 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) 18 registries database. Age at diagnosis, race/ethnicity, pathologic features, date of second primary breast cancer, cause of death, and survival were abstracted for 108 196 women. Their risk of dying of breast cancer was compared with that of women in the general population. Cox proportional hazards analysis was performed to estimate the hazard ratio (HR) for death from DCIS by age at diagnosis, clinical features, ethnicity, and treatment.

    Main Outcomes and Measures  Ten- and 20-year breast cancer–specific mortality.

    Results  Among the 108 196 women with DCIS, the mean (range) age at diagnosis of DCIS was 53.8 (15-69) years and the mean (range) duration of follow-up was 7.5 (0-23.9) years. At 20 years, the breast cancer–specific mortality was 3.3% (95% CI, 3.0%-3.6%) overall and was higher for women who received a diagnosis before age 35 years compared with older women (7.8% vs 3.2%; HR, 2.58 [95% CI, 1.85-3.60]; P < .001) and for blacks compared with non-Hispanic whites (7.0% vs 3.0%; HR, 2.55 [95% CI, 2.17-3.01]; P < .001). The risk of dying of breast cancer increased after experience of an ipsilateral invasive breast cancer (HR, 18.1 [95% CI, 14.0-23.6]; P < .001). A total of 517 patients died of breast cancer following a DCIS diagnosis (mean follow-up, 7.5 [range, 0-23.9] years) without experiencing an in-breast invasive cancer prior to death. Among patients who received lumpectomy, radiotherapy was associated with a reduction in the risk of ipsilateral invasive recurrence at 10 years (2.5% vs 4.9%; adjusted HR, 0.47 [95% CI, 0.42-0.53]; P < .001) but not of breast cancer–specific mortality at 10 years (0.8% vs 0.9%; HR, 0.86 [95% CI, 0.67-1.10]; P = .22).

    Conclusions and Relevance  Important risk factors for death from breast cancer following a DCIS diagnosis include age at diagnosis and black ethnicity. The risk of death increases after a diagnosis of an ipsilateral second primary invasive breast cancer, but prevention of these recurrences by radiotherapy does not diminish breast cancer mortality at 10 years.

    ×